AbbVie Inc., a pharmaceutical company based in North Chicago, Illinois, has made significant strides in the industry by discovering, developing, manufacturing, and selling various drugs worldwide. Among its products is Humira, a therapy administered through injection for autoimmune and intestinal Behçet's diseases and pyoderma gangrenosum. It also offers Skyrizi, Rinvoq, Imbruvica, Venclexta/Venclyxto, facial injectables, plastics and regenerative medicine, body contouring, and skincare products. The company's product line-up also includes Vraylar for depressive disorder, Duopa and Duodopa for advanced Parkinson's disease, Ubrelvy for the acute treatment of migraine, Qulipta for episodic migraine, Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure (IOP), Restasis to increase tear production, and various eye care products. Moreover, AbbVie's offerings extend to Mavyret/Maviret, a treatment for chronic hepatitis C virus (HCV); Creon, a pancreatic enzyme therapy; Lupron, which treats advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids; Linzess/Constella for irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. The company has collaborations with Calico Life Sciences LLC, REGENXBIO Inc., I-Mab Biopharma, Genmab A/S, Janssen Biotech, Inc., and Genentech, Inc. AbbVie Inc. was established in 2012 and has since become a leader in the pharmaceutical industry.